Soficitinib (ICP-332) vs TDM-180935

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: TYK2/JAK1 · full Atopic Dermatitis pipeline

Soficitinib (ICP-332)

Developed by Beijing InnoCare Pharma Tech Co.

Phase 3 in Atopic Dermatitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT06775860 (registry estimate)

No aligned efficacy figure on record for this race.

TDM-180935

Developed by Technoderma Medicines

Phase 2 in Atopic Dermatitissmall molecule
Partial signal

NCT06363461 · Phase 2 · completed

This randomized, double-blind, vehicle-controlled trial was small (24 people). The sponsor states the primary endpoint was met for the 2% ointment but reports no result for the 1% ointment and no statistics, so it is not clear how the primary comparison came out overall.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSoficitinib (ICP-332)TDM-180935
EASI-75—Trial running · NCT06775860—Not reported
IGA 0/1 with 2-point improvement—Trial running · NCT06775860—Not reported
EASI-90—Trial running · NCT06775860—Not reported
EASI, % change—Trial running · NCT06775860—Not reported

EASI-75

Soficitinib (ICP-332)
—Trial running · NCT06775860
TDM-180935
—Not reported

IGA 0/1 with 2-point improvement

Soficitinib (ICP-332)
—Trial running · NCT06775860
TDM-180935
—Not reported

EASI-90

Soficitinib (ICP-332)
—Trial running · NCT06775860
TDM-180935
—Not reported

EASI, % change

Soficitinib (ICP-332)
—Trial running · NCT06775860
TDM-180935
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Soficitinib (ICP-332): no structured comparison results are available for Atopic Dermatitis.

TDM-180935: no structured comparison results are available for Atopic Dermatitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Soficitinib (ICP-332)'s landscape · TDM-180935's landscape